BRIOTECH

BRIOTECH is a biotechnology startup based in the United States, founded in 2013, with a focused mission to revolutionize health, healing, and disinfection globally through the use of pure HOCl. The company's flagship product, BrioHOCl, is a pure form of HOCl produced from saltwater re-synthesis, and it has demonstrated remarkable efficacy in stopping the replication of various pathogens without creating resistance and persistence mechanisms. Notably, NIH testing on the world's worst pathogens showed unparalleled inactivation efficacy of BrioHOCl while maintaining lasting shelf stability and consistent safety profiles. In alignment with its purpose-driven approach, BRIOTECH allocates 5% of its gross sales to underserved populations, emphasizing support for "at-risk women, children, and indigenous people" through its foundation, BrioEarth. The company's commitment to community empowerment extends to the deployment of remotely controlled factories, furthering its efforts to have a global impact by delivering superior, pure, stable, safe, and affordably priced HOCl products to improve daily lives. With $2.00M Venture Round investment on 27th March 2024, BRIOTECH is positioned to solidify its industry leadership in the world of HOCl. As the company prepares to launch its comprehensive HOCl Codex, "The Handbook of HOCl," in summer 2021, it continues to demonstrate its dedication to advancing health and wellness on a global scale.For more information, visit brioglobal.com.